Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6%

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 1,020,000 shares, a drop of 43.6% from the January 31st total of 1,810,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 5.2% of the shares of the stock are sold short.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL opened at $2.19 on Tuesday. The company has a 50-day simple moving average of $2.23 and a 200-day simple moving average of $2.86. The company has a market cap of $89.53 million, a PE ratio of -1.06 and a beta of 1.84. Vigil Neuroscience has a 12 month low of $1.49 and a 12 month high of $6.06.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wedbush boosted their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a report on Thursday, January 23rd. William Blair began coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience presently has an average rating of “Buy” and a consensus price target of $19.75.

Institutional Trading of Vigil Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP boosted its holdings in shares of Vigil Neuroscience by 239.1% during the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock worth $831,000 after purchasing an additional 344,614 shares during the last quarter. Blair William & Co. IL acquired a new stake in Vigil Neuroscience in the 4th quarter worth about $551,000. Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 698.5% in the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock valued at $624,000 after buying an additional 321,300 shares during the period. abrdn plc increased its stake in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after acquiring an additional 293,461 shares during the last quarter. Finally, Trustees of Columbia University in the City of New York purchased a new position in shares of Vigil Neuroscience during the 4th quarter worth about $328,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.